Johnson & Johnson Announces Leading Candidate for COVID-19 Vaccine

A referral partnership with the US Department of Health and Human Services and commitment to provide one billion global vaccines for emergency pandemic control

Johnson & Johnson and BARDA are committed to investing over $ 1 billion together in research and development of the new coronavirus vaccine; The company expects to initiate phase 1 clinical trials for the candidate vaccine no later than September 2020.

For more information, please see the Romanian version of the article, here.